Showing results (471-480 of 738) with videos related to
Sort By:
Pageof 74
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.Nature Medicine|January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trialAlicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 studyR S Kristeleit, S Ghamande, A Lisyanskaya, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2025
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analysesJ Mayadev, J C Vázquez Limón, F J Ramírez Godinez, et al.Gynecologic Oncology|May 3, 2021
Uterine serous carcinomaGiorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, et al.Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 StudyIgnace Vergote, Els Van Nieuwenhuysen, Roisin E O'Cearbhaill, et al.Gynecologic Oncology|April 18, 2026
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 studyEls Van Nieuwenhuysen, Ignace Vergote, Leslie M Randall, et al.European Journal of Cancer (Oxford, England : 1990)|January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trialAna Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancerRobert W Holloway, Premal Thaker, Alberto A Mendivil, et al.Pageof 74